Vertex Buys ViaCyte for Diabetes Stem Cell Treatment
By Lucy Haggerty
Pharma Deals Review: Vol 2022 Issue 7 (Table of Contents)
Published: 14 Jul-2022
DOI: 10.3833/pdr.v2022.i7.2703 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
On the hunt for a potentially curative treatment, Vertex Pharmaceuticals has agreed to acquire ViaCyte, a developer of stem cell-derived therapies for type 1 diabetes...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS